Display options
Cite
Gill SE, Zhang Q, Keeney GL, et al. Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR. Oncotarget. 2017;8(49):85214-85223doi: 10.18632/oncotarget.19620.
Gill, S. E., Zhang, Q., Keeney, G. L., Cliby, W. A., & Weroha, S. J. (2017). Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR. Oncotarget, 8(49), 85214-85223. https://doi.org/10.18632/oncotarget.19620
Gill, Sarah E, et al. "Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR." Oncotarget vol. 8,49 (2017): 85214-85223. doi: https://doi.org/10.18632/oncotarget.19620
Gill SE, Zhang Q, Keeney GL, Cliby WA, Weroha SJ. Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR. Oncotarget. 2017 Jul 27;8(49):85214-85223. doi: 10.18632/oncotarget.19620. eCollection 2017 Oct 17. PMID: 29156714; PMCID: PMC5689604.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 27;8(49):85214-85223. doi: 10.18632/oncotarget.19620. eCollection 2017 Oct 17.

Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR.

Oncotarget

Sarah E Gill, Qing Zhang, Gary L Keeney, William A Cliby, S John Weroha

Affiliations

  1. Department of Gynecologic Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  2. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  3. Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 29156714 PMCID: PMC5689604 DOI: 10.18632/oncotarget.19620

Abstract

MISIIR is a potential target for ovarian cancer (OC) therapy due to its tissue-specific pattern of expression. 3C23K is a novel therapeutic monoclonal anti-MISIIR antibody designed to recruit effector cells and promote cell death through ADCC (antibody dependent cell-mediated cytotoxicity). Our objective was to determine the tolerability and efficacy of 3C23K in OC patient-derived xenografts (PDX) and to identify factors affecting efficacy. Quantitative RT-PCR, immunohistochemistry (IHC), and flow cytometry were used to categorize MISIIR expression in established PDX models derived from primary OC patients. We selected two high expressing models and two low expressing models for

Keywords: 3C23K; mullerian inhibiting substance receptor; ovarian cancer; patient-derived xenograft; targeted therapy

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no competing financial interests.

References

  1. Gynecol Oncol. 2008 Jan;108(1):141-8 - PubMed
  2. Am J Obstet Gynecol. 2003 Oct;189(4):1120-7 - PubMed
  3. Int J Oncol. 2009 Jun;34(6):1583-91 - PubMed
  4. Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4418-27 - PubMed
  5. Immunopharmacol Immunotoxicol. 1994 Aug;16(3):319-46 - PubMed
  6. PLoS One. 2015 May 11;10(5):e0126867 - PubMed
  7. Nat Cell Biol. 2003 May;5(5):410-21 - PubMed
  8. Nature. 2016 Feb 25;530(7591):391 - PubMed
  9. J Immunol. 2009 Jun 1;182(11):6771-8 - PubMed
  10. Clin Cancer Res. 2009 Nov 1;15(21):6709-15 - PubMed
  11. Cancer Discov. 2014 Sep;4(9):998-1013 - PubMed
  12. Oncotarget. 2017 Jun 6;8(23 ):37061-37079 - PubMed
  13. CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 - PubMed
  14. Endocrinology. 2001 Sep;142(9):4040-6 - PubMed
  15. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6396-400 - PubMed
  16. Clin Cancer Res. 1999 Nov;5(11):3488-99 - PubMed
  17. Gynecol Oncol. 2002 Nov;87(2):200-6 - PubMed
  18. Cell Immunol. 1990 Oct 1;130(1):106-17 - PubMed
  19. Biochem J. 2004 May 1;379(Pt 3):785-93 - PubMed
  20. Front Oncol. 2013 Dec 04;3:295 - PubMed
  21. Nat Rev Immunol. 2010 May;10(5):317-27 - PubMed
  22. JAMA. 2017 Jan 24;317(4):388-406 - PubMed
  23. Comp Med. 2009 Jun;59(3):234-41 - PubMed
  24. Mol Cancer Ther. 2015 Apr;14(4):973-81 - PubMed
  25. Nat Commun. 2013;4:2126 - PubMed
  26. Lab Invest. 2011 Nov;91(11):1605-14 - PubMed
  27. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  28. Clin Cancer Res. 2014 Mar 1;20(5):1288-97 - PubMed
  29. MAbs. 2014;6(5):1314-26 - PubMed
  30. FEMS Microbiol Lett. 2000 Nov 1;192(1):27-31 - PubMed

Publication Types

Grant support